ADHD treatment · drug development · FDA review
A new class of ADHD medication is under FDA review. Here is what the clinical evidence actually shows.
Centanafadine targets three neurotransmitters simultaneously — a mechanism no approved ADHD drug currently uses. The FDA has granted priority review. The target decision date is July 24, 2026.
ADHD pharmacotherapy has long been divided into two broad categories: stimulants, which primarily act on dopamine and norepinephrine and are effective for many patients, and non-stimulants, which generally have lower abuse potential but often trade some efficacy for slower onset or smaller effect size. Neither category directly targets serotonin in an ADHD-specific way.
Centanafadine, an investigational once-daily extended-release capsule developed by Otsuka Pharmaceutical, is designed to change that. If approved, it would become the first norepinephrine-dopamine-serotonin reuptake inhibitor, or NDSRI, approved for ADHD. That makes the FDA review notable not merely because a new drug is under consideration, but because the mechanism itself would expand the neurochemical model on which current ADHD treatment is built.
Why adding serotonin to the mechanism matters
Current ADHD pharmacology is built mainly on a two-neurotransmitter model. Stimulants increase dopamine and norepinephrine signaling in circuits relevant to attention and inhibitory control. Atomoxetine primarily targets norepinephrine. Serotonin, however, has long been implicated in emotional regulation, impulse control and other ADHD-relevant domains, yet no currently approved ADHD medication is designed around direct serotonin transporter inhibition.
Centanafadine’s triple mechanism
Preclinical and translational findings discussed in the evidence base suggest centanafadine increases extracellular concentrations of all three monoamines. Whether that translates into clinically meaningful advantages over existing options remains one of the key post-approval questions, if approval occurs.
What the four Phase 3 trials actually showed
The NDA is supported by four randomized, double-blind, placebo-controlled trials across pediatric, adolescent and adult populations. The broad signal is consistent, but the dose-response pattern is not uniform across age groups and needs to be interpreted carefully.
| Population | N | Doses tested | Result |
|---|---|---|---|
| Children 6–12 years | 480 | Weight-based low / high dose vs placebo, 6 weeks | High dose statistically significant on ADHD-RS-5. Low dose did not reach the primary endpoint. Separation from placebo was reported by week 1. |
| Adolescents 13–17 years | 459 | 164.4 mg / 328.8 mg vs placebo, 6 weeks, no titration | High dose statistically significant. Lower dose did not meet the primary endpoint. |
| Adults 18–55 years, trial 1 | ~440 | 200 mg / 400 mg vs placebo, 6 weeks | Both doses statistically significant on total symptom score. |
| Adults 18–55 years, trial 2 | ~430 | 200 mg / 400 mg vs placebo, 6 weeks | Both doses statistically significant, with open-label extension data suggesting maintained tolerability and symptom benefit over longer follow-up. |
Safety profile across trials
Across studies, treatment-emergent adverse events were generally reported as mild to moderate. Pediatric studies described decreased appetite, nausea, rash, fatigue, abdominal pain and somnolence among the more frequently observed events. Adult trials more commonly highlighted decreased appetite and headache.
An important theoretical advantage is lower abuse liability relative to amphetamine-based stimulants. Mechanistically, centanafadine acts through transporter reuptake inhibition rather than direct dopamine release. That distinction does not eliminate the need for full safety review, but it is relevant to access, scheduling and the population for whom the drug may eventually be considered.
Where centanafadine could fit in the treatment landscape
Regulatory timeline
Regulatory Timeline — Centanafadine
NDA submitted
Nov 25, 2025Priority review accepted
Jan 27, 2026Under FDA review
NowPDUFA decision date
Jul 24, 2026
What to watch between now and July 2026
The review process will extend beyond efficacy tables. The agency will assess the totality of the clinical evidence, adverse event profile, manufacturing quality, proposed labeling and the practical implications of dose selection across age groups. The pediatric and adolescent dose-response asymmetry is likely to be one of the more closely examined issues.
If centanafadine is approved, the next questions will be clinical rather than merely regulatory: how it is positioned against atomoxetine and other non-stimulants, whether the serotonergic component translates into measurable benefit in emotional dysregulation or executive functioning, what scheduling classification it receives, and whether pricing or insurance barriers limit actual uptake.
For patients, families and clinicians who have exhausted the current option set — or who need a non-stimulant strategy with a different pharmacologic logic — July 24, 2026 is a date worth tracking.
Sources and Evidence Base
- Otsuka Pharmaceutical press release, January 27, 2026.
- Ward et al., Pediatrics Open Science (2025).
- Ward et al., Journal of the American Academy of Child & Adolescent Psychiatry (2025).
- Adler et al., Journal of Clinical Psychopharmacology (2022).
- Mattingly et al., Journal of Clinical Psychopharmacology (2025).
- FDA priority review / PDUFA designation materials as applicable.
